Stay updated on PD-1 Inhibitor Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PD-1 Inhibitor Combo in NSCLC Clinical Trial page.

Latest updates to the PD-1 Inhibitor Combo in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed descriptions of a clinical study involving the PD-1 inhibitor JTX-4014 and its combination with vopratelimab for treating metastatic NSCLC. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference32%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check48 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check84 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check99 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to PD-1 Inhibitor Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1 Inhibitor Combo in NSCLC Clinical Trial page.